- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
- Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
- Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
- Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
- Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
- Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
More ▼
Key statistics
As of last trade, Kiromic Biopharma Inc (KRBP:QBB) traded at 2.41, 1,406.25% above the 52 week low of 0.16 set on Oct 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.55 |
---|---|
High | 2.55 |
Low | 2.39 |
Bid | -- |
Offer | -- |
Previous close | 2.41 |
Average volume | 1.22k |
---|---|
Shares outstanding | 1.29m |
Free float | 1.15m |
P/E (TTM) | -- |
Market cap | 3.10m USD |
EPS (TTM) | -29.21 USD |
Data delayed at least 15 minutes, as of May 09 2024 19:12 BST.
More ▼